熱門資訊> 正文

Sarepta关注即将发布的Elevidys 3年数据

2026-01-24 06:55

Sarepta療法(SRPT) 0

Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy the morning of Jan. 26.
The data from part 1 is in ambulatory patients with Duchenne who were four to seven years old at time of treatment.
The company will hold a webcast and conference call at 830a ET on Jan. 26.

More on Sarepta Therapeutics

Sarepta Preliminary Results: Not What The Market Wanted To Hear
Sarepta Therapeutics: Is Elevidys A Bust?
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Sarepta guides Q4 sales below estimates
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。